Clinical trials: Arthritis, Rheumatoid (RA)
Arthritis, Rheumatoid
SB-681323 In Subjects With Rheumatoid Arthritis
The purpose of this research is to find out how effective and safe SB-681323 will be in the treatment of RA when it is added to standard anti-rheumatic treatments.
- Trial name
- NCT00320450
- Testing
- SB-681323
- Where
- 41 sites in Denmark, Germany and 7 more
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA
The objective of this investigation is to identify the following problems and questions with respect to the safety and efficacy of Enbrel during the post-marketing period as required by Korea Food and Drug Administration (KFDA)'s…
- Trial name
- NCT00195403
- Testing
- Etanercept
- Where
- 4 sites in South Korea
- Volunteers
- 1,014 people
- Sponsor
- Pfizer
Rheumatoid Arthritis, Rheumatoid Arthritis (RA)
Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and reduced physical function. Although standard disease-modifying antirheumatic drugs are effective for many patients, some individuals…
- Trial name
- NCT07632846
- Testing
- Roflumilast 500 Mcg Oral Tablet
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Horus University
Rheumatoid Arthritis
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy
This observational study will evaluate the safety, tolerability and efficacy of tocilizumab in participants with moderate to severe RA who have an inadequate response to current non-biologic DMARD and/or anti-TNF therapy.
- Trial name
- NCT01362062
- Testing
- Tocilizumab
- Where
- 7 sites in India
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Refractory Lupus Nephritis, Myasthaenia Gravis
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been…
- Conditions
- Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA)
- Trial name
- KYSA-4 (NCT07403188)
- Testing
- KYV-101
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Kyverna Therapeutics
Rheumatoid Arthritis
A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment
The study is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 12 weeks daily treatment with 100 mg AP1189 in RA patients who are to start up-titration with methotrexate…
- Trial name
- EXPAND (NCT05516979)
- Testing
- 100 mg AP1189
- Where
- Moldova
- Volunteers
- 127 people
- Sponsor
- SynAct Pharma Aps
Rheumatoid Arthritis
A Non-Interventional Study in Patients With Moderate to Severe Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)
This non-interventional study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT01663506
- Where
- 3 sites in Estonia
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
Leflunomide EfficAcy Response Related to Dosing Regimen in Early Rheumatoid Arthritis
To assess the efficacy response rate at 3-months of two dosing regimen of leflunomide in DMARDs-naive patients presenting an early-RA using American College of Rheumatology 20% response rate.
- Trial name
- LEADER (NCT00596206)
- Testing
- leflunomide
- Where
- 5 sites in Czechia, Italy and 3 more
- Volunteers
- 124 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.
AD 452 is a new drug which is being developed for use in adult patients with RA. It is believed that AD 452 may modify the underlying disease of RA as well as improving RA symptoms, and in order to establish its efficacy and…
- Trial name
- NCT00141934
- Testing
- AD 452
- Where
- 10 sites in United States
- Volunteers
- 232 people
- Sponsor
- Sosei
Rheumatoid Arthritis (RA)
Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetic, and Food Effects of ARD-885 Film-coated Tablets in Healthy Chinese Subjects and Patients With Rheumatoid Arthritis
The proposed study is a randomized, double-blind, placebo-controlled single and multiple ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetic, and food effects of ARD-885 Film-coated Tablets in…
- Trial name
- NCT07266207
- Testing
- ARD-885 Tablets
- Where
- China
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Artivila (Shenzhen) Innovation Center, Ltd
Rheumatoid Arthritis (RA), Anxiety
Mobile App-Based Yoga and Meditation in Rheumatoid Arthritis
The goal of this single-blind, randomized controlled trial is to evaluate the clinical effectiveness and short-term economic impact of a mobile application-based, personalized yoga and meditation program in adult patients with…
- Conditions
- Rheumatoid Arthritis (RA), Anxiety, Depression Anxiety Disorder, Mobile Health Technology (mHealth)
- Trial name
- NCT07666594
- Testing
- Mobile App-Based Yoga and Meditation
- Where
- Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- Tugba Civi Karaaslan
Rheumatoid Arthritis
The Treat-to-target Study of RA Based on Smart System of Disease Management(SSDM)
This study evaluate the Smart System of Disease Management（SSDM）to improve the treat-to-target(T2T) and the safety of drug in the treatment of rheumatoid(RA).
- Trial name
- T2TRAonSSDM (NCT03715595)
- Testing
- SSDM group
- Where
- China
- Volunteers
- 2,200 people
- Sponsor
- Peking University People's Hospital
Rheumatoid Arthritis
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
This is a Phase IIa/b double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of RO7123520 as adjunctive therapy in participants with RA who are inadequately responding…
- Trial name
- NCT03001219
- Testing
- Anti-TNF-alpha, Methotrexate, RO7123520
- Where
- 81 sites in United States, Argentina and 9 more
- Volunteers
- 109 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis
The study aims to evaluate the predictability of early response to Certolizumab pegol in combination with Methotrexate at one year in patients with moderate to severe rheumatoid arthritis.
- Trial name
- SPEED (NCT01443364)
- Testing
- Certolizumab pegol
- Where
- 18 sites in Italy
- Volunteers
- 132 people
- Sponsor
- UCB Italy s.p.a.
Rheumatoid Arthritis (RA), Methotrexate Induced Nephrotoxicity
The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate
The primary aim of this clinical trial is to Evaluate the Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate.
- Conditions
- Rheumatoid Arthritis (RA), Methotrexate Induced Nephrotoxicity, Methotrexate Adverse Reaction
- Trial name
- NCT06641128
- Testing
- MTX SC or IM, Empagliflozin 25mg tab
- Where
- Egypt
- Volunteers
- 44 people
- Sponsor
- Tanta University
Systemic Lupus Erythematosus, Scleroderma
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
This is an open lable and single arm study, is designed to evaluate the safety and preliminary efficacy of HN2301 in Autoimmune Disease（AID）
- Conditions
- Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis
- Trial name
- SLE，SSc，RA (NCT06801119)
- Testing
- HN2301 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen MagicRNA Biotechnology Co., Ltd
Rheumatoid Arthritis
Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis
The goal of this randomised, double-blind, placebo-controlled Phase II clinical trial is to assess the safety and effect of of IHL-675A in rheumatoid arthritis patients on pain, and function according to RAPID-3.
- Trial name
- CHAPPII (NCT05942911)
- Testing
- IHL-675A, Cannabidiol, Hydroxychloroquine
- Where
- 10 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Incannex Healthcare Ltd
Rheumatoid Arthritis (RA
Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects
The goal of this clinical trial is to learn if Test Product KSHB002 shows equivalence in terms of PK , safety and immunogenicity as compared to reference product ORENCIA used to treat Rheumatoid arthritis .
- Trial name
- abatacept (NCT06929039)
- Testing
- Abatacept
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Kashiv BioSciences, LLC
Rheumatoid Arthritis
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
This multicenter, prospective, observational study will assess the efficacy of MabThera/Rituxan (rituximab) and alternative TNF-inhibitors in patients with rheumatoid arthritis who are non-responders or intolerant to a single…
- Trial name
- NCT01557348
- Where
- 215 sites in Canada, Colombia and 10 more
- Volunteers
- 1,239 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Develop Biomarkers for Assessing RA Joint Erosion
With the current therapeutic focus in rheumatoid arthritis (RA) shifting from symptom control to actual disease modification there is a growing demand for more objective and sensitive ways to evaluate structural damage in the…
- Trial name
- NCT00154947
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital